On August 22, 2024 Hanmi Pharmaceutical reported the company has signed a technology transfer agreement with domestic research and development company Novomedison for the BTK inhibitor ‘Poseltinib’ (Press release, Hanmi, AUG 22, 2024, View Source [SID1234649253]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the 14th, Hanmi Pharmaceutical announced in its ‘Semi-Annual Report’ that it had transferred Poseltinib to Novomedison on June 3rd through major contracts and research and development activities.

The technology transfer target region is the entire world. The total contract amount and the amount received were not disclosed under the agreement of both companies.

Novomedison is the new name of Genome Opinion, which signed a joint development agreement with Hanmi Pharmaceutical for Poseltinib in October 2021.

After signing the joint development agreement, Hanmi Pharmaceutical and Novomedison have signed a technology transfer agreement.

After signing the joint development agreement, Novomedison has been conducting an investigator-led clinical trial with a three-drug combination therapy using Poseltinib.

Poseltinib is a drug that Hanmi Pharmaceutical has been developing since 2010 for the indication of diffuse large B-cell lymphoma. It was exported to Eli Lilly in 2015, but the rights were returned in 2019 as its efficacy was not proven in phase 2 for patients with rheumatoid arthritis.

Since then, Hanmi Pharmaceutical has been conducting phase 2 domestic trials for follow-up development.